References of "Charlier, Corinne"
     in
Bookmark and Share    
Peer Reviewed
See detailExploration biologique actuelle du métabolisme du fer
Charlier, Corinne ULg; Plomteux, Guy ULg

in Revue de la Médecine Générale (1995), 123

Detailed reference viewed: 23 (0 ULg)
See detailLa ciclosporine A
Charlier, Corinne ULg

Conference (1995)

Detailed reference viewed: 3 (0 ULg)
See detailToxicités aiguë et chronique des drogues toxicomanogènes
Charlier, Corinne ULg

Conference (1995)

Detailed reference viewed: 3 (0 ULg)
See detailLes traitements de substitution à la méthadone: le suivi en laboratoire
Charlier, Corinne ULg

Conference given outside the academic context (1995)

Detailed reference viewed: 8 (0 ULg)
See detailMechanism of action of Tamoxifen
Charlier, Corinne ULg

Conference (1995)

Detailed reference viewed: 11 (0 ULg)
Full Text
Peer Reviewed
See detailTamoxifen activates the cell-cell adhesion function of E-Cadherin in MCF-7/6 human mammary carcinoma cells
Bracke, M.; Charlier, Corinne ULg; Bruyneel, E. et al

Poster (1994)

Detailed reference viewed: 6 (1 ULg)
Peer Reviewed
See detailEtude comparative de six systèmes d'immunodosage de la ferritine sérique au cours de maladies rhumatismales
Revenant, M. C.; Vernet, M.; Rymer, J. C. et al

in Eurobiologiste (L') (1994), XXVIII(2), 35-41

Detailed reference viewed: 8 (0 ULg)
Peer Reviewed
See detailMarqueurs tumoraux
Charlier, Corinne ULg; Plomteux, Guy ULg

in Focus Diagnostica (1994), 2

Detailed reference viewed: 4 (0 ULg)
Peer Reviewed
See detailTamoxifen restores the E-cadherin function in human breast cancer MCF-7/6 cells and suppresses their invasive phenotype
Bracke, M. E.; Charlier, Corinne ULg; Bruyneel, E. A. et al

in Cancer Research (1994), 54

Detailed reference viewed: 7 (3 ULg)
Full Text
Peer Reviewed
See detailLe tamoxifene dans le traitement du cancer du sein
Charlier, Corinne ULg; Colin, Claude ULg; Merville, Marie-Paule ULg et al

in Journal de Gynécologie, Obstétrique et Biologie de la Reproduction (1994), 23(7), 751-6

Tamoxifen is the most often prescribed non steroidal antioestrogenic agent in the world for breast cancer. Worldwide collaboration. has centralized the results, of different trials throughout the world on ... [more ▼]

Tamoxifen is the most often prescribed non steroidal antioestrogenic agent in the world for breast cancer. Worldwide collaboration. has centralized the results, of different trials throughout the world on oral adjuvant therapy in the early stages of breast cancer. A significative regression of the tumour was observed in most cases. Moreover, recent epidemiological studies suggest that tamoxifen could prevent new contralateral primary tumours. The risk of the disease should thus be reduced by the prophylactic use of antioestrogens such as tamoxifen. Investigations using a variety of models have evaluated the effect of tamoxifen on tumour promotion and cell growth. Tamoxifen-induced growth inhibition is associated with major changes in biochemical events in cultured human breast cancer cells including cell proliferation or growth factor production. Growth inhibition of oestrogen-responsive human breast cancer cells is associated with an induced secretion of autoinhibitory polypeptides (TGF beta) and an antagonistic effect on the synthesis of proliferative proteins (TGF alpha,...). The first step in the mechanism of action of the drug is binding of tamoxifen to the oestrogen receptors. Development of resistance to tamoxifen treatment is a great problem in treatment of breast cancer patients and the mechanism of resistance will require further study: under the influence of the drug, tumours could become remodelled as selected subpopulations emerge resistant-tamoxifen. The fact that some breast cancers which are oestrogen receptor-negative respond to antioestrogen suggests that parallel but separate pathways for oestrogen and antioestrogen action may exist. This paper summarizes the results of the most recent studies concerning this promising drug. [less ▲]

Detailed reference viewed: 205 (11 ULg)
See detailRôle du laboratoire dans les intoxications aiguës
Charlier, Corinne ULg

Conference (1994)

Detailed reference viewed: 17 (0 ULg)
Peer Reviewed
See detailValeurs de référence de la ferritine sérique chez l'adulte
Vernet, M.; Revenant, M. C.; Charlier, Corinne ULg et al

in Annales de Biologie Clinique (1994), 52

Detailed reference viewed: 25 (0 ULg)
Peer Reviewed
See detailEtude multicentrique du dosage de la transferrine déficiente en acide sialique par deux techniques chromatographiques
Vernet, M.; Renversez, J. C.; Revenant, M. C. et al

in Annales de Biologie Clinique (1994), 52

Detailed reference viewed: 6 (2 ULg)
Peer Reviewed
See detailLa transferrine déficiente en acide sialique: un nouveau marqueur de l'éthylisme chronique ?
Charlier, Corinne ULg; Plomteux, Guy ULg

in Annales Pharmaceutiques Belges (1993), 3

Detailed reference viewed: 15 (0 ULg)